Surgical treatment of locally advanced desmoid tumor of the anterior abdominal wall

Desmoid tumor (DO) is a rare monoclonal connective tissue tumor arising from deep soft tissues, characterized by invasive growth and a tendency to local relapses and incapable of metastasis [1].

The purpose of presenting this clinical case is to assess the significance of timely diagnosis, the choice of an individually correct treatment method, tactics of further observation, therapy.

To achieve this goal, a number of literature sources were studied, a clinical case of surgical treatment of a desmoid tumor of the anterior abdominal wall was presented in our medical institution (Northwestern State Medical University named after I.I.Mechnikov, St. Petersburg).

The difficulty of the case was the significant size of the indolent tumor, insensitive to systemic therapy, in a young man, and therefore the decision on surgical treatment tactics was also ambiguous. In each clinical case, it is worth taking an individual approach to treatment tactics. When choosing observational tactics, strict outpatient monitoring and regular follow-up should be performed.

1. Fletcher C.D.M., Bridge J.A., Hogendoorn P., Mertens F. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press, 2013. 468 р.

2. Penel N., Coindre J.M., Bonvalot S. et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France // Europ. J. Cancer. 2016. Vol. 58. Р. 90–96. doi: 10.1016/j.ejca.2016.02.008.

3. Spear M.A., Jennings L.C., Mankin H.J. et al. Individualizing management of aggressive fibromatosis // Int. J. Radiat. Oncol. Biol. Phys. 1998. Vol. 40 (3) 6. Р. 37–45. doi: 10.1016/s0360-3016(97)00845-6.

4. Ballo M.T., Zagars G.K., Pollack A., Pisters P.W., Pollack R.A. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy // J. сlin. Oncol. 1999. Vol. 17 (1). Р. 158–167. doi: 10.1200/JCO.1999.17.1.158.

5. Guadagnolo B.A., Zagars G.K., Ballo M.T. Long-term outcomes for desmoid tumors treated with radiation therapy // Int. J. Radiat. Oncol. Biol. Phys. 2008. Vol. 71 (2). Р. 441–447. doi: 10.1016/j.ijrobp.2007.10.013.

6. Azzarelli A., Gronchi A., Bertulli R. et al. Lowdose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis // Cancer. 2001. Vol. 92 (5). Р. 1259–1264. doi: 10.1002/10970142(20010901)92:5<1259:aid-cncr1446>3.0.co;2-y.

7. Palassini E., Frezza A M., Mariani L. et al. Long-term efficacy of methotrexate plus vinblastine/ vinorelbine in large series of patients affected by desmoid-type fibromatosis // Cancer. J. 2017. Vol. 23 (2). Р. 86–91. doi: 10.1097/PPO.0000000000000254.

8. Hansmann A., Adolph C., Vogel T., Unger A., Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors // Cancer. 2004. Vol. 100 (3). Р. 612–620. doi: 10.1002/cncr.11937.

9. Libertini M., Mitra I., Van der Graaf et al. Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response // Clin. Sarcoma. Res. 2018. Vol. 8. Р. 13. doi: 10.1186/s13569-018-0100-3.

10. Chugh R., Wathen J.K., Patel S.R. et al. Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial // Clin. Cancer. Res. 2010. Vol. 16 (19). Р. 4884–4891. doi: 10.1158/1078-0432.CCR-10-1177.

11. Kasper B., Gruenwald V., Reichardt P. et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumors — final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG) // Europ. J. Cancer. 2017. Vol. 76. Р. 60–67. doi: 10.1016/j.ejca.2017.02.001.

12. Penel N., Le Cesne A., Bonvalot S. et al. Surgical versus non-surgical approach in primary desmoid-type fi bromatosis patients: a nationwide prospective cohort from the French Sarcoma Group // Europ. J. Cancer. 2017. Vol. 83. Р. 125– 131. doi: 10.1016/j.ejca.2017.06.017.

13. Salas S., Dufresne A., Bui B. et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation // J. clin. Oncol. 2011. Vol. 29 (26). Р. 3553–3558. doi: 10.1200/JCO.2010.33.5489.